Outcome in Adult Low-Grade Glioma: The Impact of Prognostic Factors and Treatment
Neurol 69:1366-1373, Schiff,D.,et al, 2007
Clinicopathologic Conference, Oligdendroglioma II/IV with IDH1 R132H mutation and codelation of 1p and 19q
NEJM 375:2381-2389, Case 38-206, 2016
Statins and Intracerebral Hemorrhage
Arch Neurol 69:39-45,13, Hackam,D.G,et al, 2012
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
A 31-Year-Old Woman with a Transformed Low-Grade Glioma
JAMA 303:967-976, Warnke,P.C., 2010
Natalizumab: A Double-Edged Sword?
Ann Neurol 66:262-263, DeAngelis,L., 2009
Posterior Reversible Encephalopathy Syndrome, Part 1: Fundamental Imaging and Clinical Features
AJNR 29:1036-1042, Bartynski,W.S., 2008
What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
Steroid Treatment for Myasthenia Gravis
Muscle Nerve 25:115-121, Rivner,M.H., 2002
Long-Term Outcome of Low-Grade Oligodendroglioma and Mixed Glioma
Neurol 54:1442-1448,1402, Olson,J.D.,et al, 2000
Prethrombolysis Brain Imaging:Trends and Controversies
AJNR 18:1830-1834, Castillo,M., 1997
New Treatments for Migraine: CGRP Monoclonal Antibodies, Gepants, and Ditans
BMJ 390:e085564, Burch, R. & Rittenberg, E., 2025
Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Tenecteplase Versus Standard of Care for Minor Ischaemic Stroke with Proven Occlusion (TEMPO-2): A Randomised, Open Label, Phase 3 Superiority Trial
Lancet 403:2597-2605, Coutts,S.B.,et al, 2024
Endovascular Therapy or Medical Management Alone for Isolated Posterior Cerebral Artery Occlusion: A Multicenter Study
Stroke 54:928-937, Sabben,C.,et al, 2023
Management of Possible Multiple Sclerosis
NEJM 388:2195-2190, , 2023
Primary Diffuse Leptomeningeal Melanocytosis, A Diagnoatic Conundrum
Neurol 101:e576-3580, Selvarajan,J.M.P.,et al, 2023
Endovascular Treatment and Thrombolysis for Acute Ischemic Stroke in Patients with Premorbid Disability or Dementia
Stroke 53:e204-e217, Ganesh, A.,et al, 2022
Thrombectomy versus Medical Management in Mild Strokes due to Large Vessel Occlusion: Exploratory Analysis from the EXTEND-IA Trials and a Pooled International Cohort
Ann Neurol 92:364-378, Sarraj, A.,et al, 2022
Does Capturing Debris During TAVR Prevent Strokes?
NEJM 387:1318-1319, Carroll, J.D. & Saver, J.L., 2022
Administering Thrombolysis for Acute Ischemic Stroke in Patients Taking Direct Oral Anticoagulants
JAMA Neurol 78:515-518, Seiffge, D.J.,et al, 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Endovascular Therapy for Stroke Due to Basilar Artery Occlusion
Stroke 52:3410-3413, Nguyen, T.N. & Strbian, D., 2021
Medical Management vs Mechanical Thrombectomy for Mild Strokes
JAMA Neurol 77:16-24, Goyal, N.,et al, 2020
Thrombolytic Therapy for Acute Central Retinal Artery Occlusion
Stroke 51:687-695, Mac Grory, B.,et al, 2020
Intravenous Thrombolysis for Suspected Ischemic Stroke with Seizure at Onset
Ann Neurol 86:770-779, Polymeris, A.A.,et al, 2019
Primary Thrombectomy in tPA (Tissue-Type Plasminogen Activator) Eligible Stroke Patients with Proximal Intracranial Occlusions
Stroke 49:265-269, Fischer, U.,et al, 2018
Arteriovenous Malformations of the Brain
NEJM 376:1859-1866, Solomon, R.A. & Connolly, E.S., 2017
Direct Mechanical Thrombectomy Versus Combined Intravenous and Mechanical Thrombectomy in Large-Artery Anterior Circulation Stroke
Stroke 48:2912-2918, Fischer, U.,et al, 2017
Treatment and Outcome of Hemorrhagic Transformation after Intravenous Alteplase in Acute Ischemic Stroke
Stroke 48:e343-e361, Yaghi, S.,et al, 2017
Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic STroke
Stroke 47:581-641, Demaerschalk, B.M.,et al, 2016
Carotid Near-Occlusion: A Comprehensive Review, Part 2- Prognosis and Treatment, Pathophysiology, Confusions, and Areas for Improvement
AJNR 37:200-204, Johansson, E. & Fox, A.J., 2016
Infective Endocarditis
Lancet 387:882-893, Cahill, T.J. & Prendergast, B.D., 2016
Repeated Intravenous Thrombolysis for Early Recurrent Stroke
Stroke 47:2133-2135, Kahles, T.,et al, 2016
Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension
NEJM 375:1119-1130,1183, Hutchinson, P.J.,et al, 2016
Dexamethasone & Supportive Care with or without Whole Brain Radiotherapy in Treating Patients with Non-Small Cell Lung Cancer with Brain Metastases Unsuitable for Resection or Stereotactic Radiotherapy (QUARTZ): Results from a Phase 3,Non-Inferiority, Randomised Trial
Lancet 388:2004-2014, Mulvenna, P.,et al, 2016
Drip and Ship Versus Direct to Comprehensive Stroke Center
Stroke 48:233-238, Holodinsky, J.K.,et al, 2016
Microbleed Status and 3-Month Outcome After Intravenous Thrombolysis in 717 Patients with Acute Ischemic Stroke
Stroke 46:2458-2463,2403, Turc, G.,et al, 2015
Treatment Concepts for Wake-Up Stroke and Stroke with Unknown Time of Symptom Onset
Stroke 46:2707-2713, Thomalla, G. & Gerloff, C., 2015
Intravenous Fibrinolytic Therapy in Central Retinal Artery Occlusion
JAMA Neurol 72:1148-1154, Schrag, M.,et al, 2015
4.5-Hour Time Window for Intravenous Thrombolysis with Recombinant Tissue-Type Plasminogen Activator is Established Firmly
Stroke 45:912-913,916, Schellinger, P.D. & Kohrmann, M., 2014
The 4.5-HourTime Window for Intravenous Thrombolysis with Intravenous Tissue-Type Plasminogen Activator is Not Firmly Established
Stroke 45:915-915,916, Wechsler, L.R., 2014
Reperfusion Therapies for Wake-Up Stroke
Stroke 45:1869-1875, Buck, D.,et al, 2014
Safety of Thrombolysis in Patients with Acute Ischemic Stroke and Cerebral Cavernous Malformations
Stroke 45:1846-1848, Erdur, H.,et al, 2014
Early Transfer of Patients with Stroke to Comprehensive Centers is Necessary
Stroke 45:3748-3749,3752, Sheth, K.N., 2014
Early Transfer of Patients with Stroke to Comprehensive Stroke Centers is not Necessary
Stroke 45:3750-3751,3752, Langhorne, P., 2014
Tumor Necrosis Factor-Alpha Inhibitors: Risk of Malignancy
UpToDate January, Stone, J.H., 2013